The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of PRUNE2 and PCA3 expression as metastasis predictors in Gleason 7 prostate cancer.
 
Richard C. Lauer
No Relationships to Disclose
 
Marc Barry
No Relationships to Disclose
 
Jin Wu
No Relationships to Disclose
 
Ji-Hyun Lee
No Relationships to Disclose
 
Dennis J. McCance
No Relationships to Disclose
 
Ruofei Du
No Relationships to Disclose
 
Arpit Rao
No Relationships to Disclose
 
Andrey S. Dobroff
Patents, Royalties, Other Intellectual Property - AAVP Biosystems
 
Emmanuel Dias-Neto
Patents, Royalties, Other Intellectual Property - AAVP Biosystems; AAVP Biosystems (I); Mbrace Therapeutics; Mbrace Therapeutics (I)
 
Isan Chen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Aragon Pharmaceuticals
 
Renata Pasqualini
Stock and Other Ownership Interests - Ablaris Therapeutics; Ablaris Therapeutics (I)
Research Funding - Arrowhead Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - AAVP Biosystems; AAVP Biosystems (I); Arrowhead Pharmaceuticals; Arrowhead Pharmaceuticals (I); Mbrace Therapeutics; Mbrace Therapeutics (I); Merck; Merck (I)
 
Wadih Arap
Stock and Other Ownership Interests - Ablaris Therapeutics; Ablaris Therapeutics (I)
Research Funding - Arrowhead Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - AAVP Biosystems; AAVP Biosystems (I); Arrowhead Pharmaceuticals; Arrowhead Pharmaceuticals (I); Mbrace Therapeutics; Mbrace Therapeutics (I); Merck; Merck (I)